TY  - JOUR
T1  - THe dilemma of prostate-specific antigen testing
AU  - Leach R, Thompson IM
Y1  - 2012/06/11
N1  - 10.1001/archinternmed.2012.1226
JO  - Archives of Internal Medicine
SP  - 835
EP  - 836
VL  - 172
IS  - 11
N2  - 
For a man with prostate cancer, treatment decision making is daunting. If the tumor is high grade, decision making may be straightforward because disease-specific mortality is high despite the toxicity of combined therapies that are proved to reduce mortality (eg, radiation and hormonal therapy).1 For a man with an aggressive tumor, while decision making requires considerable thought, information, and support by the treating physician, the possibility of adverse effects often dims when there is an opportunity to improve survival.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.1226
UR  - http://dx.doi.org/10.1001/archinternmed.2012.1226
ER  -